0001193125-19-212818.txt : 20190805 0001193125-19-212818.hdr.sgml : 20190805 20190805135056 ACCESSION NUMBER: 0001193125-19-212818 CONFORMED SUBMISSION TYPE: 253G2 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190805 DATE AS OF CHANGE: 20190805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LunaDNA, LLC CENTRAL INDEX KEY: 0001741687 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 830631362 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 253G2 SEC ACT: 1933 Act SEC FILE NUMBER: 024-10903 FILM NUMBER: 19998209 BUSINESS ADDRESS: STREET 1: 415 SOUTH CEDROS AVENUE STREET 2: SUITE 260 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858 299-4669 MAIL ADDRESS: STREET 1: 415 SOUTH CEDROS AVENUE STREET 2: SUITE 260 CITY: SOLANA BEACH STATE: CA ZIP: 92075 FORMER COMPANY: FORMER CONFORMED NAME: LunaTrust LLC DATE OF NAME CHANGE: 20180523 253G2 1 d775289d253g2.htm 253G2 253G2

Filed Pursuant to Rule 253(g)(2)

File No. 024-10903

 

LOGO

SUPPLEMENT NO. 1 DATED AUGUST 5, 2019

TO THE OFFERING CIRCULAR DATED MAY 14, 2019

This document supplements, and should be read in conjunction with, the offering circular of LunaDNA, LLC (the “Company”, “we”, “our” or “us”), dated May 14, 2019 (the “Offering Circular”). Unless otherwise defined in this supplement, capitalized terms used in this supplement shall have the same meanings as set forth in the Offering Circular.

* * *

The purpose of this supplement is to modify the definition of the Data Type “Health Records—Clinical Reports (ex. Lab results)” and to make a corresponding modification to the number of shares per submission that we will issue. Our previous assignment of 4 shares per submission of Data Type: Health Records – Clinical Reports (ex. Lab results) assumed a submission would include typically between two (2) and eight (8) individual records recorded during a single patient encounter with a care delivery organization, with each individual record representing a different resource type, such as vital signs, immunizations, procedures, test results or conditions. Due to manner in which individual records derived from a single patient encounter typically become available to patients, we have determined that the better method of share allocation is to allocate one (1) share per individual record/resource type submitted instead of four (4) shares for a group of individual records assumed to derive from a single patient encounter. We have therefore revised the share consideration tables on page 1 and page 38 of the Offering Circular to revise the information for the Data Type formerly referred to as Health Records – Clinical Reports (ex. Lab results) and we have also revised the description of such data type on page 40 of the Offering Supplement.

The table appearing on page 1 is updated to replace the line for Health Records – Clinical Reports (ex. Lab results) as follows:

 

Member Data Provided    Shares Issued      Estimated Fair
Market Value
 

Health Records – Clinical Data

     1      $ 0.07  

 

-1-


The table appearing on page 38 is updated to replace the line for Health Records – Clinical Reports (ex. Lab results) as follows:

 

Data Type

  

Shares
per
Initial
File

  

Extra
Submissions*
Allowed at Initial
File Value

  

Subtotal
shares at
Initial
File
Value

  

Number of
Additional
Files** of
Same
Type
Allowed
(@ 10
shares
each)

  

Subtotal
Additional
Shares(@
10 shares
each)

  

Maximum
Possible
Shares

Health Records –

Clinical Data

   1    No maximum for unique individual records    Dependent on number of patient encounters and unique individual records generated and submitted each year

This former description of Health Records – Clinical Reports (ex. Lab results) is replaced with the following:

 

   

Health Records - Clinical Data: The Electronic Health Record is a record of clinical services for patient encounters in a care delivery organization. These encounters generate clinical data that is converted into a digital format by healthcare system software (such as Epic and Cerner) in alignment with current digital standards. This digital clinical data typically includes, but is not limited to, the following individual records or resource types (also known as component file types): vital signs, immunizations, procedures, test results and conditions. We intend to accept all digital clinical data component file types but we reserve the right to decline individual records that we consider duplicative of previously submitted individual records or otherwise not valuable towards discovery.

* * *

This supplement is not complete without, and may not be delivered or used except in connection with, the Offering Circular.

We might further amend or supplement the Offering Circular from time to time by filing additional amendments or supplements. You should read the entire Offering Circular, as amended or supplemented, before deciding whether to purchase shares.

 

-2-

GRAPHIC 2 g775289g0804151343016.jpg GRAPHIC begin 644 g775289g0804151343016.jpg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